This investigation aimed to design, develop, and optimize intranasal nanoemulsion for brain targeted delivery of lurasidone hydrochloride for the management and treatment of schizophrenia. The design of experiment supported optimization of high-pressure homogenization (HPH) process was executed for the manufacturing of lurasidone loaded nanoemulsion. The nanoemulsion comprising of lurasidone hydrochloride (10 mg/mL), 20% Oil_mix, 25% surfactant and, 55% aqueous phase (w/w) was processed with HPH at optimized conditions to get droplet size in the nano range. The droplet size of optimized nanoemulsion was found to be 48.07 ± 3.29 nm with a polydispersity index of 0.31 ± 0.01. The optimized translucent nanoemulsion (% transmittance of 88.56 ± 2.47) was found to be non-toxic to sheep nasal mucosa and stable for six months. The results of ex vivo diffusion study revealed the improvement in drug diffused by mucoadhesive nanoemulsion (MLNE) (1.41 × 10⁻⁴ ± 1.11 × 10⁻⁵ cm²/min) as compared to the solution (1.15 × 10⁻⁴ ± 1.35 × 10⁻⁵ cm²/min). The results of pharmacodynamic studies in mice uncover the highest inhibition of compulsive behavior (64.63%) and spontaneous locomotor activity (60.87%) shown by MLNE. This may be due to increased bioavailability in a brain, and possibly confirms the potential of nanoemulsion in targeting the brain through nasal route in the treatment of schizophrenia.

这项研究旨在设计，开发和优化鼻内纳米乳剂，用于盐酸鲁拉西酮的脑靶向给药，以治疗和治疗精神分裂症。实验设计的支持高压均质化（HPH）工艺的优化被执行，以生产负载卢拉西酮的纳米乳液。纳米乳液，包含盐酸卢拉西酮（10 mg / mL），20％油_混合物在最佳条件下，用HPH对25％的表面活性剂和55％的水相（w / w）进行处理，以使液滴尺寸达到纳米范围。发现优化的纳米乳液的液滴尺寸为48.07±3.29nm，多分散指数为0.31±0.01。发现优化的半透明纳米乳剂（％透射比为88.56±2.47）对绵羊鼻粘膜无毒，并且可以稳定六个月。离体扩散研究的结果表明，与溶液（1.15×10 ^-4 ±1.35× ）相比，粘膜粘附纳米乳剂（MLNE）的药物扩散性有所改善（1.41×10 ^-4 ±1.11×10 ^-5 cm ² / min）。10 ^-5厘米²/ min）。在小鼠中进行的药效学研究结果显示，MLNE显示出对强迫行为的最高抑制（64.63％）和自发运动能力（60.87％）。这可能是由于脑中的生物利用度增加，并且可能证实了纳米乳剂在治疗精神分裂症中通过鼻途径靶向脑的潜力。